At long last luvelta-T is shelved, and Sutro seeks a new focus.
ApexOnco Front Page
Recent articles
The Japanese group licenses sapablursen from Ionis for $280m.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Enzomenib might be the most promising agent so far, on a cross-trial basis.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
And the company might one day follow Galapagos into decentralised manufacturing.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
